Gainers
- Context Therapeutics Inc. CNTX rose 48.6% to $9.30 in pre-market trading as the company announced data from ONA-XR in early breast cancer. The company said ONA-XR decreased proliferation in tumors with high PR+ at baseline in early breast cancer.
- American Virtual Cloud Technologies, Inc. AVCT rose 23.4% to $2.32 in pre-market trading. American Virtual Cloud Technologies shares jumped over 82% on Thursday after the company announced it projects revenues of its Kandy Business Unit to grow from $14.3 million in 2020 to approximately $18.8 million in 2021 and in excess of $37 million in 2022.
- C3.ai, Inc. AI rose 22% to $39.15 in pre-market trading after the company said it won a $500 million Department of Defense agreement.
- VYNE Therapeutics Inc. VYNE rose 15.2% to $1.59 after surging 14% on Thursday.
- Monopar Therapeutics Inc. MNPR rose 14.5% to $4.57. Monopar recently advanced dosing of Camsirubicin to higher level than tested in any previous clinical trial.
- Applied DNA Sciences, Inc. APDN rose 12.5% to $5.72 in pre-market trading after the company reported better-than-expected Q4 sales results.
- Oracle Corporation ORCL rose 11.5% to $99.05 in pre-market trading after the company reported stronger-than-expected results for its second quarter and increased its share buyback by $10 billion.
- Energy Focus, Inc. EFOI rose 10.5% to $3.90 in pre-market trading. Energy Focus recently announced the launch of its nUVo virus-targeted UVC air disinfectors to the public.
- Nu Holdings Ltd. NU rose 8.2% to $11.18 in pre-market trading after jumping 15% on Thursday. The company priced its IPO at $9 per share.
- Broadcom Inc. AVGO rose 6% to $618.43 in pre-market trading after the company reported better-than-expected results for its fourth quarter and issued strong sales forecast for the current quarter. The company announced a $10 billion buyback and boosted its quarterly dividend from $3.60 to $4.10 per share.
- Progenity, Inc. PROG rose 5.5% to $2.68 in pre-market trading after declining 9% on Thursday.
- Longeveron Inc. LGVN rose 5% to $20.00 in pre-market trading. Longeveron was recently granted Orphan Drug Designation by the FDA for Lomecel-B to treat infants with hypoplastic left heart syndrome.
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.
Check out these big penny stock gainers and losers
Losers
- Code Chain New Continent Limited CCNC fell 25% to $0.90 in pre-market trading after dipping more than 29% on Thursday.
- Everbridge, Inc. EVBG fell 22% to $89.95 in pre-market trading after the company said David Meredith has notified the board of his intention to resign from his role as Chief Executive Officer.
- Chewy, Inc. CHWY shares fell 8.8% to $51.31 in pre-market trading after the company reported Q3 earnings results.
- Inspira Technologies Oxy B.H.N. Ltd. IINN shares fell 5.7% to $4.67 in pre-market trading. Inspira Technologies shares jumped 84% on Thursday after the company announced a strategic agreement with Innovimed for the potential deployment of 1,522 ART systems in Poland, Czech Republic & Slovakia.
- iPower Inc. IPW shares fell 5.4% to $3.14 in pre-market trading after surging 16% on Thursday.
- Ensysce Biosciences, Inc. ENSC fell 4.9% to $4.73 in pre-market trading. Zacks Small-Cap Research gave the stock a $23 price valuation on Tuesday.
APDNApplied DNA Sciences Inc
$0.17857.14%
AVGOBroadcom Inc
$240.003.29%
CHWYChewy Inc
$34.960.14%
CNTXContext Therapeutics Inc
$1.1416.3%
EFOIEnergy Focus Inc
$1.22-0.81%
ENSCEnsysce Biosciences Inc
$10.1522.9%
IINNInspira Technologies Oxy BHN Ltd
$1.203.45%
IPWiPower Inc
$0.83100.12%
LGVNLongeveron Inc
$1.74-1.69%
MNPRMonopar Therapeutics Inc
$23.15-3.54%
NUNu Holdings Ltd
$10.452.05%
ORCLOracle Corp
$171.401.34%
VYNEVYNE Therapeutics Inc
$2.9113.2%
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in